Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
Part of paid clinical trials in New York, New York.
- Sponsor
- Columbia University
- Study ID
- NCT05635045
- Phase
- PHASE2
- Status
- Completed
Conditions
- Transthyretin Amyloidosis
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - 105 Years
- Healthy Volunteers
- Accepted
Interventions
- I 124-Evuzamitide — DRUGAmyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
Study Details
This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan. Ten previously scanned subjects re-consented to undergo another 124I-evuzamitide PET scan. Demographic, clinical and phenotypic data were collected to characterize potential changes since their previous scans.
Key Dates
- Start date
- Jul 8, 2022
- Status verified
- Jul 2025
- Primary completion
- May 7, 2024
- Completion
- Jun 12, 2024
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- DIAGNOSTIC
Arms
- Active Comparator: Stabilizer OnlySubjects treated with tafamidis selected to re-scan to determine the change over time in Evuzamitide uptake
- Active Comparator: Silencer OnlySubjects treated with vutrisiran selected to re-scan to determine the change over time in Evuzamitide uptake
- Active Comparator: Stabilizer and Silencer (tafamidis + patisiran)Subjects treated with tafamidis and patisiran selected to re-scan to determine the change over time in Evuzamitide uptake
- Active Comparator: Stabilizer and Silencer (vutrisiran + diflunisal)Subjects treated with vutrisiran and diflunisal selected to re-scan to determine the change over time in Evuzamitide uptake
Primary Outcome Measure
Median of Uptake of Evuzamitide as Measured by Volume of Interest in Milliliters [ Time Frame: Up to one month after imaging ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Columbia University Irving Medical Center | New York | New York | 10032 | - |
Find similar trials in New York, NY
By research site
Related Studies
- Non-interventional Study of Patients With Transthyretin (ATTR) AmyloidosisRecruiting · AstraZeneca · La Jolla, California
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPHASE3 · Recruiting · Eidos Therapeutics, a BridgeBio company · La Jolla, California
- Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEFRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic AmyloidosisPHASE2 · Recruiting · Oregon Health and Science University · Portland, Oregon